EyePoint, Inc.
EYPTHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeEyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The $34.9M market capitalization puts EYPT squarely in micro-cap range for its industry. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.
Market Cap
$34.9M
Beta
1.68
P/E (TTM)
—
P/E (Fwd)
-0.19
EPS (TTM)
$-3.75
EPS (Fwd)
$-2.16
ROE
-148.7%
ROA
-74.9%
Cash
$180.5M
Total Debt
$22.4M
Free CF
-$155.0M
52W Change
-96.7%
Annual Financials
Cash vs Debt
Where EYPT stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, EYPT finished 95.81% below its 150-day moving average ($10.50) and 96.25% below its 200-day moving average ($11.72). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is EYPT overbought or oversold?
At the October 20, 2026 close, EYPT's RSI(14) was 11.8, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
EyePoint, Inc. holds $180.5M in cash against $22.4M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$155.0M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -148.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $41.4M (2022) to $31.4M (2025), a 24% decline worth watching.
EyePoint, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing EYPT.